抗けいれん薬の世界市場レポート 2024年

抗けいれん薬の市場規模は近年着実に成長しています。2023年の183億9,000万米ドルから2024年には190億8,000万米ドルへと、CAGR3.7％で拡大します。このような成長は、てんかんの有病率の増加、診断能力の進歩、抗けいれん薬の適応拡大、個別化医療への注目、発作性疾患の治療に対する認識と教育の高まりなど、いくつかの要因によるものです。これらの要因が総合的に、この時期の抗けいれん薬の開発と採用に寄与しています。

てんかんの有病率の増加は、近い将来、抗けいれん薬市場の拡大を促進するものと思われます。てんかんは、脳に影響を及ぼし、しばしば発作を引き起こす神経疾患です。この慢性的で非伝染性の脳疾患は、あらゆる年齢層の個人に影響を及ぼします。抗けいれん薬は、てんかん患者の発作を抑制するために使用される薬剤の一種です。てんかん発作の引き金となる脳内の異常な電気的活動を抑制することで、てんかん症状の管理を補助します。例えば、2023年2月に世界保健機関（WHO）が発表したデータによると、世界中で年間約500万人がてんかんと診断されていると推定されています。高所得国では、年間100万人あたり約49人がてんかんと診断されているが、低・中所得国では、この数字は100万人あたり139人にまでエスカレートしています。したがって、てんかんの有病率の増加は、抗けいれん薬市場の成長軌道を大きく後押ししています。

2023年の抗けいれん薬市場で最大の地域は北米です。アジア太平洋は、予測期間中、抗けいれん薬世界市場レポートにおいて最も急成長する地域となる見込みです。抗けいれん薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の抗けいれん薬市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の抗けいれん薬の市場規模実績と成長、2018～2023年
• 世界の抗けいれん薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の抗けいれん薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• ピリミジンジオン
• ベンゾジアゼピン系
• フルクトース誘導体
• 芳香族アリルアルコール
• バルプロイルアミド
• カルボキサミド
• ブロマイド
• その他
• 世界の抗けいれん薬市場、新薬世代別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 第一世代
• 第二世代
• 第三世代
• 世界の抗けいれん薬市場、投与形態別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• カプセル
• タブレット
• クリーム
• 液体
• 直腸ジェル
• その他
• 世界の抗けいれん薬市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 片頭痛
• てんかん
• 神経因性疼痛
• 不安
• 線維筋痛症
• 双極性障害
• 境界性人格障害
• 世界の抗けいれん薬市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• クリニック
• その他のエンドユーザー

第7章 地域と国の分析

• 世界の抗けいれん薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の抗けいれん薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗けいれん薬市場の競合情勢
• 抗けいれん薬市場の企業プロファイル
  • Eisai Co Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Johnson &Johnson Services Inc .
  • Novartis AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

“Anticonvulsants Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anticonvulsants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anticonvulsants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anticonvulsants market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Pyrimidinediones; Benzodiazepines; Fructose Derivatives; Aromatic Allylic Alcohols; Valproylamides; Carboxamides; Bromides; Other Types
• 2) By Drug Generation: First Generation; Second Generation; Third Generation
• 3) By Dosage: Capsule; Tablet; Cream; Liquid; Rectal Gel; Other Dosages
• 4) By Application: Migraine; Epilepsy; Neuropathic Pain; Anxiety; Fibromyalgia; Bipolar Disorder; Borderline Personality Disorder
• 5) By End-User: Hospitals; Clinics; Other End-Users
• Companies Mentioned: Eisai Co Ltd.; GlaxoSmithKline plc; Pfizer Inc.; Johnson & Johnson Services Inc .; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anticonvulsants, also known as anti-seizure medications or antiepileptics, are a class of drugs designed to prevent and treat seizures or convulsions by regulating abnormal electrical activity in the brain. Additionally, these medications are employed to address conditions such as nerve pain and restless leg syndrome.

The primary types of anticonvulsants include pyrimidinediones, fructose derivatives, aromatic allylic alcohols, valproylamides, carboxamides, bromides, and others. Pyrimidines are heterocyclic aromatic organic compounds found in nucleic acids, proteins, starches, and other biological molecules. Anticonvulsants are categorized into first-generation, second-generation, and third-generation drugs, and are available in various dosage forms such as capsules, tablets, liquids, rectal gel, among others. They find applications in treating conditions such as migraine, epilepsy, neuropathic pain, anxiety, fibromyalgia, bipolar disorder, and borderline personality disorder. These medications are utilized in diverse end-user industries, including hospitals, clinics, and others.

The anticonvulsants market research report is one of a series of new reports from The Business Research Company that provides anticonvulsants market statistics, including anticonvulsants industry global market size, regional shares, competitors with a anticonvulsants market share, detailed anticonvulsants market segments, market trends and opportunities, and any further data you may need to thrive in the anticonvulsants industry. This anticonvulsants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticonvulsants market size has grown steadily in recent years. It will grow from $18.39 billion in 2023 to $19.08 billion in 2024 at a compound annual growth rate (CAGR) of 3.7%. The growth observed in the historical period can be attributed to several factors, including the increased prevalence of epilepsy, advancements in diagnostic capabilities, the expansion of indications for anticonvulsants, a focus on personalized medicine, and heightened awareness and education regarding the treatment of seizure disorders. These factors collectively contributed to the development and adoption of anticonvulsant medications during this period.

The anticonvulsants market size is expected to see steady growth in the next few years. It will grow to $21.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The anticipated growth in the forecast period can be attributed to several factors, including the ongoing increase in epilepsy cases, expanding applications in neuropsychiatry, the development of new anticonvulsant agents, a growing emphasis on mental health, and global health initiatives. Major trends expected in the forecast period include the development of pediatric applications and formulations, a shift towards extended-release formulations, increased adoption of generic versions of anticonvulsants, integration with digital health solutions, and ongoing research on the neuroprotective effects of these medications.

The upsurge in the prevalence of epilepsy is poised to propel the expansion of the anticonvulsants market in the foreseeable future. Epilepsy stands as a prevalent neurological disorder affecting the brain and often resulting in seizures. This chronic and non-communicable brain ailment affects individuals across all age groups. Anticonvulsants, a class of medications, are utilized to suppress seizures among individuals with epilepsy. They assist in managing epilepsy symptoms by curtailing abnormal electrical activity in the brain, which triggers seizures, although they do not offer a definitive cure for the condition. For instance, data from the World Health Organization in February 2023 revealed an estimated annual diagnosis of epilepsy in approximately 5 million individuals worldwide. In high-income countries, around 49 per 0.1 million people are diagnosed with epilepsy yearly, while in low- and middle-income countries, this figure escalates to as high as 139 per 0.1 million individuals. Hence, the escalating prevalence of epilepsy significantly propels the growth trajectory of the anticonvulsants market.

The burgeoning geriatric populace is anticipated to drive the expansion of the anticonvulsant market in the forthcoming years. The geriatric demographic pertains to the segment encompassing elderly individuals, typically defined as those aged 65 and above. Anticonvulsants play a pivotal role within this demographic, especially in managing seizures and epilepsy-common conditions among elderly individuals. For instance, projections from the World Health Organization in October 2022 indicate that by 2030, one in every six individuals globally will be aged 60 or older, totaling 1.4 billion people, up from 1 billion in 2020. Additionally, the global population aged 60 and older is expected to double by 2050, reaching 2.1 billion individuals. Notably, during the period from 2020 to 2050, there will be a surge of 426 million individuals aged 80 or older. Therefore, the swelling geriatric population significantly propels the expansion of the anticonvulsant market.

Product development emerges as a prominent trend gaining momentum within the anticonvulsants market. Leading companies in this sector are dedicatedly focused on innovating new products to fortify their market position and attain a competitive edge. For instance, Lupin Limited, an India-based pharmaceutical entity, introduced Rufinamide tablets USP, 200 mg and 400 mg, through an abbreviated new drug application in December 2022. Rufinamide, an anticonvulsant drug, is employed in conjunction with other medications to manage seizures in individuals afflicted with Lennox-Gastaut syndrome, a severe form of epilepsy characterized by varied seizures, behavioral disruptions, and developmental delays, typically originating in childhood.

Significant emphasis is placed on the introduction and approval of advanced drug solutions by major players operating in the anticonvulsants market to secure a competitive advantage. These novel drug solutions, upon approval by national regulatory bodies, aim to notably impact the availability of advanced therapies for patients grappling with seizures related to diverse syndromes. For instance, in March 2022, UCB, a Belgium-based biopharmaceutical firm, announced the approval by the U.S. Food and Drug Administration (FDA) for FINTEPLA (fenfluramine) oral solution CIV. This approval caters to treating seizures linked to Lennox-Gastaut syndrome in patients aged two years and above. Fenfluramine demonstrates efficacy in managing challenging seizure types such as drop seizures, characterized by sudden loss of muscular tone, leading to a limp state and an elevated risk of falling and injury. Fenfluramine, working through a distinct mechanism, complements and differs from existing epileptic drugs, enabling its continued use alongside current antiseizure regimens. The clinical trials evidenced statistically significant enhancements in patients with LGS when utilizing fenfluramine based on the Clinical Global Impression Scale (CG-I) in the global placebo-controlled phase 3 trial.

In May 2021, Jazz Pharmaceuticals Inc., an Ireland-based biopharmaceutical company, successfully acquired GW Pharmaceuticals plc for a total of $7.6 billion. This strategic acquisition serves to broaden, diversify, and enrich Jazz's portfolio business strategy by incorporating complementary therapies into its commercial portfolio and innovative pipeline. Additionally, the acquisition strengthens Jazz's neuroscience business through the addition of Epidiolex, a cannabis-based epilepsy treatment developed by GW Pharmaceuticals plc. The latter, headquartered in the UK, is a pharmaceutical company primarily engaged in the manufacturing of anticonvulsant medications.

Major companies operating in the anticonvulsants market report are Eisai Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services Inc ., Novartis AG, Jazz Pharmaceuticals Inc., UCB SA, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Sanofi SA, Zydus Lifesciences Ltd., Lupin Limited, Ratiopharm Group, Kannalife Inc., Neuropathix Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, AstraZeneca plc, Glenmark Pharmaceuticals Limited, Laurus Labs Limited, Biocon Limited, Recordati S.p.A., Neurocrine Biosciences Inc.

North America was the largest region in the Anticonvulsants market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global anticonvulsants market report during the forecast period. The regions covered in the anticonvulsants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anticonvulsants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anticonvulsant market consists of sales of drugs such as phenobarbital, phenytoin, carbamazepine, levetiracetam, ethosuximide, clonazepam, diazepam, lorazepam, and midazolam. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Anticonvulsants Market Characteristics

3. Anticonvulsants Market Trends And Strategies

4. Anticonvulsants Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Anticonvulsants Market Size and Growth

• 5.1. Global Anticonvulsants Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Anticonvulsants Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Anticonvulsants Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anticonvulsants Market Segmentation

• 6.1. Global Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pyrimidinediones
• Benzodiazepines
• Fructose Derivatives
• Aromatic Allylic Alcohols
• Valproylamides
• Carboxamides
• Bromides
• Other Types
• 6.2. Global Anticonvulsants Market, Segmentation By Drug Generation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• First Generation
• Second Generation
• Third Generation
• 6.3. Global Anticonvulsants Market, Segmentation By Dosage, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Capsule
• Tablet
• Cream
• Liquid
• Rectal Gel
• Other Dosages
• 6.4. Global Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Migraine
• Epilepsy
• Neuropathic Pain
• Anxiety
• Fibromyalgia
• Bipolar Disorder
• Borderline Personality Disorder
• 6.5. Global Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Other End-Users

7. Anticonvulsants Market Regional And Country Analysis

• 7.1. Global Anticonvulsants Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Anticonvulsants Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anticonvulsants Market

• 8.1. Asia-Pacific Anticonvulsants Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anticonvulsants Market

• 9.1. China Anticonvulsants Market Overview
• 9.2. China Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anticonvulsants Market

• 10.1. India Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anticonvulsants Market

• 11.1. Japan Anticonvulsants Market Overview
• 11.2. Japan Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anticonvulsants Market

• 12.1. Australia Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anticonvulsants Market

• 13.1. Indonesia Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anticonvulsants Market

• 14.1. South Korea Anticonvulsants Market Overview
• 14.2. South Korea Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anticonvulsants Market

• 15.1. Western Europe Anticonvulsants Market Overview
• 15.2. Western Europe Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anticonvulsants Market

• 16.1. UK Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anticonvulsants Market

• 17.1. Germany Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anticonvulsants Market

• 18.1. France Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anticonvulsants Market

• 19.1. Italy Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anticonvulsants Market

• 20.1. Spain Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anticonvulsants Market

• 21.1. Eastern Europe Anticonvulsants Market Overview
• 21.2. Eastern Europe Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anticonvulsants Market

• 22.1. Russia Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anticonvulsants Market

• 23.1. North America Anticonvulsants Market Overview
• 23.2. North America Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anticonvulsants Market

• 24.1. USA Anticonvulsants Market Overview
• 24.2. USA Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anticonvulsants Market

• 25.1. Canada Anticonvulsants Market Overview
• 25.2. Canada Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anticonvulsants Market

• 26.1. South America Anticonvulsants Market Overview
• 26.2. South America Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anticonvulsants Market

• 27.1. Brazil Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anticonvulsants Market

• 28.1. Middle East Anticonvulsants Market Overview
• 28.2. Middle East Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anticonvulsants Market

• 29.1. Africa Anticonvulsants Market Overview
• 29.2. Africa Anticonvulsants Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Anticonvulsants Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Anticonvulsants Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anticonvulsants Market Competitive Landscape And Company Profiles

• 30.1. Anticonvulsants Market Competitive Landscape
• 30.2. Anticonvulsants Market Company Profiles
  • 30.2.1. Eisai Co Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. GlaxoSmithKline plc
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Pfizer Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Johnson & Johnson Services Inc .
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Anticonvulsants Market Competitive Benchmarking

32. Global Anticonvulsants Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Anticonvulsants Market

34. Anticonvulsants Market Future Outlook and Potential Analysis

• 34.1 Anticonvulsants Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Anticonvulsants Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Anticonvulsants Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer